Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion Lumos, LTQ Orbitrap Elite
ORGANISM(S): Homo Sapiens (human) Mus Musculus (mouse)
TISSUE(S): B Cell, Lung, B-lymphocyte, Epithelial Cell, Kidney Cell, Kidney
DISEASE(S): Lung Cancer,Lymphoma
SUBMITTER: Dennis Goldfarb
LAB HEAD: Ben Major
PROVIDER: PXD006139 | Pride | 2017-12-07
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
DB_TMT_abemaciclib.zip | Other | |||
H2228_drug_treatment_LFQ.zip | Other | |||
H2228_lysate_abemaciclib_TMT.zip | Other | |||
MA1373_H2228_DMSO_MIBMS_Emily.raw | Raw | |||
MA1375_H2228_DMSO_MIBMS_Emily.raw | Raw |
Items per page: 1 - 5 of 41 |
Molecular cancer research : MCR 20171113 2
The cellular and organismal phenotypic response to a small-molecule kinase inhibitor is defined collectively by the inhibitor's targets and their functions. The selectivity of small-molecule kinase inhibitors is commonly determined <i>in vitro</i>, using purified kinases and substrates. Recently, competitive chemical proteomics has emerged as a complementary, unbiased, cell-based methodology to define the target landscape of kinase inhibitors. Here, we evaluated and optimized a competitive multi ...[more]